Survey of Retail Prices (CMS-10241)

Forms and Documents

Document Name	Status
CMS-10241 - Supporting Statement B (2021 version 2).docx Supporting Statement B	2021-09-02
CMS-10241 - Supporting Statement A (2021 version 5).docx Supporting Statement A	2021-09-02

IC Document Collections

IC ID	Document Title	Status
201423	National Average Drug Acquisition Cost (NADAC) Survey Instruction	Modified

ICR Details

OMB Control No: 0938-1041	ICR Reference No: 202109-0938-001
Status: Received in OIRA	Previous ICR Reference No: 201805-0938-013
Agency/Subagency: HHS/CMS	Agency Tracking No: CMCS
Title: Survey of Retail Prices (CMS-10241)
Type of Information Collection: Revision of a currently approved collection	Common Form ICR:  No
Type of Review Request: Regular	Date Submitted to OIRA: 09/02/2021

	Requested	Previously Approved
Expiration Date	36 Months From Approved	09/30/2021
Responses	72,000	30,000
Time Burden (Hours)	36,000	15,000
Cost Burden (Dollars)	0	0

---

Abstract: CMS is performing a "Survey of Retail Prices: Payment and Utilization Rates, and Performance Rankings." This study is divided into two parts. Part I focuses on the retail community pharmacy consumer prices. It also includes reporting by the States of payment and utilization rates for the 50 most widely prescribed drugs, and comparing State drug payment rates with the national retail survey prices. The template for States to use to complete (Effective July 1, 2013, CMS has suspended Part I of the nationwide retail survey for collecting information about consumer purchase prices, pending funding decisions.) Part II of this contract focuses on the retail community pharmacy ingredient costs. This segment provides for a survey of the average acquisition costs of all covered outpatient drugs purchased by retail community pharmacies. The prices will be updated on at least a monthly basis.

---

Authorizing Statute(s): PL: Pub.L. 109 - 171 6001 Name of Law: Deficit Reduction Act
  

Citations for New Statutory Requirements: PL: Pub.L. 109 - 171 6001(f) Name of Law: Deficit Reduction Act

---

Associated Rulemaking Information
RIN:	Stage of Rulemaking:	Federal Register Citation:	Date:
	Not associated with rulemaking

---

Federal Register Notices & Comments
60-day Notice:	Federal Register Citation:	Citation Date:
	86 FR 27623	05/21/2021
30-day Notice:	Federal Register Citation:	Citation Date:
	86 FR 49332	09/02/2021
Did the Agency receive public comments on this ICR? No

---

Number of Information Collection (IC) in this ICR: 1

IC Title	Form No.	Form Name
National Average Drug Acquisition Cost (NADAC) Survey	CMS-10241	National Average Drug Acquisition Cost (NADAC) Survey Request for Information

---

ICR Summary of Burden

	Total Request	Previously Approved	Change Due to New Statute	Change Due to Agency Discretion	Change Due to Adjustment in Estimate	Change Due to Potential Violation of the PRA
Annual Number of Responses	72,000	30,000	0	42,000	0	0
Annual Time Burden (Hours)	36,000	15,000	0	21,000	0	0
Annual Cost Burden (Dollars)	0	0	0	0	0	0

Burden increases because of Program Change due to Agency Discretion: Yes

Burden Increase Due to: Miscellaneous Actions

Burden decreases because of Program Change due to Agency Discretion: No

Burden Reduction Due to:

Short Statement: We propose to expand the number of retail community pharmacies that are sent the survey request each month. Currently, 2,500 pharmacies are randomly drawn each month and have the option of voluntarily completing the survey request. To further expand the survey population to derive more responses each month and ensure statistical validity to the NADAC pricing file, We propose to expand the survey population to up to 6,000 retail community pharmacies surveyed each month. Overall, the change would add 21,000 hr (total) per year. We also propose to add a Survey Cover Sheet that explains protections for drug acquisition cost data submitted by pharmacies. The document has no burden.

---

Annual Cost to Federal Government: $0

Does this IC contain surveys, censuses, or employ statistical methods? Yes Part B of Supporting Statement

Does this ICR request any personally identifiable information (see OMB Circular No. A-130 for an explanation of this term)? Please consult with your agency's privacy program when making this determination.     No

Does this ICR include a form that requires a Privacy Act Statement (see 5 U.S.C. §552a(e)(3))? Please consult with your agency's privacy program when making this determination.     No

Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]? No

Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]? No

Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)? No

Is this ICR related to the Pandemic Response? No

---

Common Form ICR:  No

---

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).

The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:

(a) It is necessary for the proper performance of agency functions;

(b) It avoids unnecessary duplication;

(c) It reduces burden on small entities;

(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;

(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;

(f) It indicates the retention periods for recordkeeping requirements;

(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:

(i) Why the information is being collected;

(ii) Use of information;

(iii) Burden estimate;

(iv) Nature of response (voluntary, required for a benefit, or mandatory);

(v) Nature and extent of confidentiality; and

(vi) Need to display currently valid OMB control number;

(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.

(i) It uses effective and efficient statistical survey methodology (if applicable); and

(j) It makes appropriate use of information technology.

If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.

Certification Date: 09/02/2021

---